National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Menopausal Hormone Replacement Therapy (HRT)
    Posted: 07/09/2002    Updated: 10/03/2006



Links to NCI Materials






Links to Other Materials






Current Clinical Trials



Page Options
Print This Page
Print This Document
View Entire Document
E-Mail This Document
Quick Links
Director's Corner

Dictionary of Cancer Terms

NCI Drug Dictionary

Funding Opportunities

NCI Publications

Advisory Boards and Groups

Science Serving People

Español
Quit Smoking Today
NCI Highlights
Report to Nation Finds Declines in Cancer Incidence, Death Rates

High Dose Chemotherapy Prolongs Survival for Leukemia

Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E

The Nation's Investment in Cancer Research FY 2009

Past Highlights
Related Pages
Breast Cancer Home Page
NCI's gateway for information about breast cancer.

Colon and Rectal Cancer Home Page
NCI's gateway for information about colon and rectal cancer.

Ovarian Cancer Home Page
NCI's gateway for information about ovarian cancer.
Links to Other Materials

Menopausal Hormone Therapy Information from NIH
The links on this page point to information resources, including the most current from the National Institutes of Health (NIH), on both long-term and short-term hormone use, and other concerns related to women's health during and after menopause.

NIH Asks Participants in Women's Health Initiative Estrogen-Alone Study to Stop Study Pills, Begin Follow-up Phase
A March 2, 2004 announcement from the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health concerning the decision to have WHI participants in the estrogen-alone arm of the study stop taking study medications and enter the follow-up phase.

Estrogen and Estrogen with Progestin Therapies for Postmenopausal Women
Following a review of data from the Women's Health Initiative study, the Food and Drug Administration (FDA) on Jan. 8, 2003, began advising women and health care professionals about important new safety changes to labeling of all estrogen and estrogen with progestin products for use by postmenopausal women.

NHLBI Stops Trial of Estrogen Plus Progestin Due to Increased Breast Cancer Risk, Lack of Overall Benefit
A July 9, 2002, announcement from the National Heart, Lung and Blood Institute (NHLBI) of the National Institutes of Health concerning the decision to stop early a major clinical trial of the risks and benefits of combined estrogen and protestin in healthy menopausal women due to an increased risk of invasive breast cancer.

The Women's Health Initiative (WHI)
A page of information about the WHI maintained by the National Heart, Lung, and Blood Institute (NHLBI), the initiative's lead sponsor.

Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women
Principal results from the Women's Health Initiative randomized controlled trial, as published in the July 17, 2002, issue of the Journal of the American Medical Association (JAMA).

U.S. Preventive Services Task Force & HRT
To determine the current status of benefits and harms of hormone replacement therapy (HRT) use, systematic searches of the literature on HRT were conducted for the U.S. Preventive Services Task Force.

< Previous Section  |  Next Section >


A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov